Heneicomycin is structurally similar to efrotomycin, mocimycin (kirromycin) and X-5108 (geldinomycin). Comparisons were limited because of the small supplies available. All antibiotics show the same in vitro antibacterial spectrum although some test cultures were less sensitive to efrotomycin. Heneicomycin compared favorably with efrotomycin when given subcutaneously or per os against infections with Moraxella bovis and Streptococcus pyogenes. The rapid elimination of heneicomycin observed following oral administration may account for its poor activity against a Bordetella bronchiseptica infection where efrotomycin is effective. It appears more like X-5108 than efrotomycin biologically. The disaccharide on efrotomycin may account for the difference observed.
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Heneicomycin", produced by Streptomyces filipinensis, is related structurally to efrotomycin'-), mocimycin (kirromycin)3) and X-5108 (goldinomycin)3). Heneicomycin differs from X-5108 in lacking the hydroxyl at carbon-3 of the pyran ring. Because of the structural similarities of this group of antibiotics, we have compared their antibacterial activities in so far as supplies permitted.
In vitro antibacterial activities are shown in Table 1 . None of these agents has outstanding in vitro activity. Comparisons show X-5108, mocimycin and heneicomycin to have similar spectra and MIC's. Some of the test bacteria which were sensitive to these three drugs were less sensitive to efrotomycin.
Supplies of X-5108, mocimycin, and heneicomycin were insufficient to permit much testing for in vivo efficacy. The available data are summarized in Table 2 . The methods have been described previously). Heneicomycin and efrotomycin are equally effective by both routes of administration against either Moraxella bovis or Streptococcus pyogenes infections. However, efrotomycin is more active than heneicomycin by gavage against the Bordetella bronchiseptica infection. X-5108 and mocimycin. are inactive by the oral route, as well as subcutaneously, against this infection. Heneicomycin was not tested against the B. bronchiseptica infection by subcutaneous injection. The differences in the in vivo efficacy of these drugs may be due to different rates of absorption and excretion of agents in infections that progress at different rates. In the Moraxella bovis infection the mean (lay of death of untreated infected control animals was less than 0.5 day while it was 2.7 days in the Bordetella bronchiseptica infection. Thus a drug that was excreted fairly rapidly might still be active in the M. bovis infection. However, it would not be effective in the Bordetella bronchiseptica infection Wit did not produce sufficiently high and prolonged cidal serum levels to reduce the challenge bacteria to a number which could be controlled by the host defenses. Efrotomycin does not kill rapidly in vitro". It has the same mode of action* as mocimycins). Indeed structural similarities indicate the agents in this group may act at the same site and could mimic efrotomycin in rate of kill.
Blood concentrations were investigated by dosing randomized groups of CFI female mice by * WANG , C. C.: Personal Communication. No growth on nonmedicated agar after 24 hours; growth occurred after 48 hours incubation . a Test organisms were grown for 16 hours in brain heart broth (including 5 % horse serum when necessary) dil uted to 103 in fresh medium and spot inoculated onto the surface of antibiotic supplemental agar . The number of viable cells inoculated in each spot varied from 3 x 102 to 7 x 103. Plates were scored visually after 24 and 48 hour incubation at 37°C . Concentrations tested=400, 350, 300, 250, 200, 150, 100, 50, 25, 12.5, 6 .2, 3.1, 1.6, 0.8 and 0.4 #g/ml. At this dose there was a prolongation of mean survival time. " Data were reported previously in reference 4 . 
